UNLABELLED Recent publications described many discrepant findings about thyroid "stunning" after the administration of (131)I diagnostic activities to patients with differentiated thyroid carcinoma. Stunning may play a major role in reducing the therapeutic efficacy of high (131)I activities given for ablation therapy. METHODS Participation in a multicenter study to investigate differences in...

UNLABELLED We retrospectively evaluated our single-center clinical experience with (90)Y-ibritumomab tiuxetan and (131)I-tositumomab for therapy of refractory non-Hodgkin's lymphoma (NHL). We evaluated the hypothesis that the patient-specific dosing regimen used with (131)I-tositumomab results in less bone marrow toxicity than does the weight-based dosing regimen used with (90)Y-ibritumomab tiu...

OBJECTIVE To compare the probe detection method with the image quantification method when estimating (131)I biokinetics and radiation doses to the red marrow and whole body in the treatment of thyroid cancer patients. MATERIALS AND METHODS Fourteen patients with metastatic thyroid cancer, without metastatic bone involvement, were submitted to therapy planning in order to tailor the therapeuti...

UNLABELLED Prestimulation with recombinant human thyroid-stimulating hormone (rhTSH) augments radioiodine (131)I therapy for benign nontoxic multinodular goiter. The purpose of this study was to determine the optimal time interval between rhTSH and (131)I administration to enhance thyroid radioactive iodine uptake (RAIU). METHODS Patients were randomized, in a 2-factorial design, to receive e...

Targeted radioimmunotherapy in non-Hodgkin's B-cell lymphoma (NHL) offers an efficacious therapy and minimal toxicity compared to conventional chemotherapy. Iodine 131 tositumomab ((131)I-TST) is a murine monoclonal antibody against the CD20 cell surface protein and is directly covalently conjugated to (131)I, a radioactive beta and gamma emitter. While initially approved for use in relapsed, r...

the primary treatment of thyroid carcinoma is surgery and the outcome depends on its extent. the post-operative management alternatives in thyroid carcinoma include thyroid hormone, radio-iodine ablation (i-131 na), external beam radiation therapy (ebrt) and occasionally adjuvant chemotherapy. this retrospective study analyzes the managements of 153 patients (102, 51), age range 10-96 years, me...

Tositumomab/iodine-131 tositumomab (Bexxar) and ibritumomab tiuxetan (Zevalin) are radioimmunoconjugates targeting the CD20 antigen. Both agents are approved in the United States for use in relapsed or refractory, indolent or transformed, B-cell lymphoma. These agents are well tolerated and have the highest levels of single-agent activity observed in these histologies. This review will summariz...

OBJECTIVE To present the case of a radioiodine therapy-naïve thyroid cancer patient with postthyroidectomy diplopia. CLINICAL PRESENTATION AND INTERVENTION A 63-year-old male patient presented with goiter. Histology performed after thyroidectomy proved follicular thyroid cancer. Without (131)I therapy, diplopia occurred from metastasis to the right medial rectus muscle. Improvement followed a...

AIMS To report 5 year prostate-specific antigen outcomes in men undergoing prostate brachytherapy with caesium 131 at a single institution. MATERIALS AND METHODS All patients who underwent prostate brachytherapy with caesium 131 at our institution and had at least 24 months of follow-up were included in this study. The results are reported by risk group (low, intermediate and high) as well as...